QQ客服 官方微博 反馈留言

	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
	Han, Baohui; Li, Kai; Wang, Qiming; Zhang, Li; Shi, Jianhua; Wang, Zhehai; Cheng, Ying; He, Jianxing; Shi, Yuankai; Zhao, Yizhuo
刊名	JAMA ONCOLOGY
	2018
卷号	4期号:11
ISSN号	2374-2437
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3416502
专题	昆明医科大学
推荐引用方式 GB/T 7714	Han, Baohui,Li, Kai,Wang, Qiming,et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial[J]. JAMA ONCOLOGY,2018,4(11).
APA	Han, Baohui.,Li, Kai.,Wang, Qiming.,Zhang, Li.,Shi, Jianhua.,...&Sun, Yan.(2018).Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial.JAMA ONCOLOGY,4(11).
MLA	Han, Baohui,et al."Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial".JAMA ONCOLOGY 4.11(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。